The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1572
ISSUE 1572
May 20, 2019
Omadacycline (Nuzyra) - A New Tetracycline Antibiotic
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
May 20, 2019 (Issue: 1572)
The FDA has approved omadacycline (Nuzyra – Paratek),
a semisynthetic tetracycline derivative, for once-daily
IV and oral treatment of community-acquired bacterial
pneumonia (CAP) and acute bacterial skin and skin
structure infections (ABSSSIs) in adults.
... more
- KE Barber et al. Omadacycline enters the ring: a new antimicrobial contender. Pharmacotherapy 2018; 38:1194.
- S Villano et al. Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections. Future Microbiol 2016; 11:1421.
- MA Pfaller et al. Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe is part of the 2016 SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 2018; 62:e02327.
- S Jain et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med 2015; 373:415.
- R Stets et al. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med 2019; 380:517.
- Drugs for common bacterial infections in adults. Med Lett Drugs Ther 2017; 59:171.
- Delafloxacin (Baxdela) - a new fluoroquinolone antibiotic. Med Lett Drugs Ther 2018 26; 60:49.
- W O’Riordan et al. Omadacycline for acute bacterial skin and skin-structure infections. N Engl J Med 2019; 380:528.
- Approximate WAC. WAC = wholesaler acquisition cost or manufacturer’s published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: Analysource® Monthly. May 5, 2019. Reprinted with permission by First Databank, Inc. All rights reserved. ©2019. www.fdbhealth.com/policies/drug-pricing-policy.

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: Omadacycline (Nuzyra) - A New Tetracycline Antibiotic
Article code: 1572b
Electronic, downloadable article - $45
Article code: 1572b
Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian